Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA.
Charge modification by succinylation or cis-aconitylation of the terminal epsilon NH2 functions of the amino acid lysine in human serum albumin, resulted in polyanionic compounds with an anti-HIV-1 activity in the low nanomolar concentration range. After iv injections in rats of the negatively charged albumins (NCAs), a dose dependent elimination pattern was observed indicating a saturable eliminations pathway. The Michaelis-Menten parameters Vmax and K(m) were 62 +/- 8 micrograms.min-1.kg-1 and 16 +/- 4 micrograms.ml-1 (Clintr 3.9 +/- 1.1 ml.min-1.kg-1) and 74 +/- 6 micrograms.min-1.kg-1 and 11 +/- 2 micrograms.ml-1 (Clintr 6.7 +/- 1.2 ml.min-1.kg-1) for aconitylated-HSA (Aco-HSA) and succinylated-HSA (Suc-HSA) respectively, using 125I-labelled proteins. The volume of distribution (V) of both compounds was approximately 60 ml.kg-1. Coadministration of poly-inosinic acid and formaldehyde treated albumin showed a marked inhibition of blood clearance indicating that the compounds are mainly cleared from the bloodstream by scavenger receptors on liver and spleen endothelial cells and macrophages. The Michaelis-Menten constant K(m) was remarkably higher when the hydrophobic flurophore fluorescein was covalently linked to the protein, indicating that the affinity for the scavenger receptors is largely decreased by FiTC conjugation. The latter observation may have implications for the kinetic behavior of drug-carrier preparations if antiviral drugs like AZT or PMEA are linked to these intrinsic active carriers. In contrast to other polyanionic compounds like heparins and dextran sulfate, these NCAs did not exhibit acute toxicity and had no effect on blood coagulation. They neither had an effect on the lymphocyte proliferation. Studies on immunogenicity of the homologous derivatized albumins in rats did not show a significant response. The present pharmacokinetic and toxicologic data of Suc-HSA and Aco-HSA show that both compounds are interesting preparations for studies in SIV infected monkeys and AIDS patients.
Swart
P J
PJ
Groningen Institute for Drug Studies, University Centre for Pharmacy, The Netherlands. P.J.Swart@farm.rug.nl
Beljaars
E
E
Smit
C
C
Pasma
A
A
Schuitemaker
H
H
Meijer
D K
DK
D000156:Aconitic Acid / Q000276:immunology / Q000493:pharmacokinetics* / Q000633:toxicity; D000818:Animals; D000998:Antiviral Agents / Q000276:immunology / Q000493:pharmacokinetics* / Q000633:toxicity; D001777:Blood Coagulation / Q000187:drug effects; D002250:Carbon Radioisotopes; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D016650:Fluorescein-5-isothiocyanate / Q000737:chemistry; D015497:HIV-1 / Q000187:drug effects; D015498:HIV-2 / Q000187:drug effects; D006801:Humans; D007457:Iodine Radioisotopes; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D011955:Receptors, Drug / Q000378:metabolism; D012709:Serum Albumin / Q000276:immunology / Q000493:pharmacokinetics* / Q000633:toxicity; D014018:Tissue Distribution
D000998:Antiviral Agents; D002250:Carbon Radioisotopes; D004337:Drug Carriers; D007457:Iodine Radioisotopes; D011955:Receptors, Drug; D012709:Serum Albumin; C034877:succinylalbumin; D000156:Aconitic Acid; D016650:Fluorescein-5-isothiocyanate